Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year Results

M. Piccart

JNCI Journal of the National Cancer Institute

selection of Cancer Chemotherapy for a Patient by an In Vitro Assay Versus a Clinician

Daniel D. Von Hoff, John F. Sandbach, Gary M. Clark, +5

JNCI Journal of the National Cancer Institute

Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia

M. Piccart, Jean Klášterský, F. Meunier, +3

Antimicrobial Agents and Chemotherapy

Klebsiella PneumoniaeImmunologyPathologyEscherichia ColiPharmacotherapy +15

Characterisation of complete responders to combination chemotherapy for advanced breast cancer: A retrospective EORTC breast group study

Eva Tomiak, M. Piccart, F Mignolet, +7

European Journal of Cancer

Complete RespondersAdvanced Breast CancerBreast OncologyOncologyCancer Management +4

Biology of breast cancer during pregnancy using genomic profiling

Hamdy A. Azim, S. Brohée, Fedro A. Peccatori, +12

Endocrine Related Cancer

Breast OncologyEngineeringCancer PathologyGynecologyPathology +15

Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer

M. Piccart, K. Bertelsen, Gavin Stuart, +25

International Journal of Gynecological Cancer

Advanced ovarian cancer: Three-year results of a 6–8 month, 2-drug cisplatin-containing regimen

M. Piccart, James L. Speyer, James C. Wernz, +6

European Journal of Cancer and Clinical Oncology

Advanced Ovarian CancerMedicineMetronomic TherapyGynecology2-Drug Cisplatin-containing Regimen +6

A phase I/II trial of BAY 43–9006 and gemcitabine in advanced solid tumors and in advanced pancreatic cancer

Lillian L. Siu, Chris H. Takimoto, Ahmad Awada, +5

Journal of Clinical Oncology

Signal TransductionPancreatic CancerGastrointestinal OncologyMedicineMetronomic Therapy +12

Phase II studies of Elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer

Jaap Verweij, J. Wanders, Anette Lynge Nielsen, +7

Annals of Oncology

Breast OncologyOncologyMedicineColorectal CancerBreast Cancer +5

Comprehensive analysis integrating both clinicopathological and gene expression data in more than 1,500 samples: Proliferation captured by gene expression grade index appears to be the strongest prognostic factor in breast cancer (BC)

Christos Sotiriou, P. Wirapati, Sherene Loi, +7

Journal of Clinical Oncology

Breast OncologyEstrogen ReceptorPathologyGene Expression ProfilingTumor Biology +18